Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 2 Burkitt Lymphoma 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasm, Residual 1 Lymphoma, Follicular 1 Lymphoma, B-Cell 1

Interventions

Rituximab 16 Cyclophosphamide 16 Prednisone 7 Doxorubicin 7 pirtobrutinib 6 fludarabine 6 Vincristine 6 Lenalidomide 6 venetoclax 5 pembrolizumab 5 fludarabine phosphate 5 Etoposide 5 Bendamustine Hydrochloride 5 ibrutinib 4 acalabrutinib 4 Specimen Handling 4 Magnetic Resonance Spectroscopy 4 Dexamethasone 4 CT-P10 4 polatuzumab vedotin 3 etoposide phosphate 3 Immunotherapy, Adoptive 3 tazemetostat 2 liposomal doxorubicin 2 Nivolumab 2 Injections 2 Ifosfamide 2 Gemcitabine 2 Cisplatin 2 Carboplatin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Lymphoma, B-Cell × tisagenlecleucel × Clear all

NCT04234061 2024-11-07

TARMAC

Peter MacCallum Cancer Centre, Australia

Phase 2 Active not recruiting

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡